Technology Bundle ID: TAB-2716

Methods of Treating or Preventing Pruritis (Itch)

Request More Info
Licensing Contact:
Primary Inventors: 
Mark Hoon (NIDCR)
Santosh Mishra (NIDCR)
Development Stage: 
Pre-clinical (in vivo)
Development Status: 
  • Early-stage
  • In vitro data available
Institute or Center: 

This technology provides a novel method of treating or preventing pruritis (itch) using natriuretic polypeptide b (Nppb) blocking agents. Itch (also known as pruritis) is a sensation that may be perceived as an unpleasant skin irritation and may drive an urge to scratch. Conditions such as, for example, psoriasis, atopic dermatitis, renal failure, liver cirrhosis and some cancers may cause persistent itch. Itch is triggered by somatosensory neurons expressing the ion channel TRPV1 (transient receptor potential cation channel subfamily V member 1). The inventors of this technology show that the Nppb is expressed in a subset of TRPV1 neurons and found that Nppb-/- mice selectively lose all behavioral responses to itch-inducing agents. Nppb triggered potent scratching when injected intrathecally in wild-type and Nppb-/- mice. Itch responses were blocked by toxin-mediated ablation of Nppb-receptor-expressing cells, but a second neuropeptide, gastrin-releasing peptide, still induced strong responses in the toxin-treated animals.

  • Therapeutics for preventing or treating pruritis/itching.
  • Screening of novel Nppb blocking agents.
  • A new mode of treating itch and itch induced conditions using selective Nppb antagonists.


PCT Application PCT/US2014/068541
Filed on 2014-12-04
US Application 61/912,334
Filed on 2013-12-05
US Pat 10,583,173

Issued 2020-03-10
US Pat 9,987,330

Issued 2018-06-05


Mishra SK, Hoon MA.
PMID 23704570


Jan 16, 2014

Data Source: